From Treatment Discontinuation to Aggressive Recurrence: A Cautionary Case Report of Rapid Progression to Invasive Carcinoma Following Torimifene-Induced Hepatotoxicity and Drug Withdrawal in a Patient With Completely Resected Intraductal Papillary Carcinoma.
Discontinuation of adjuvant endocrine therapy due to toxicity can lead to rapid cancer progression, underscoring the need for careful management and monitoring.
Where it sits
this study against the rest of the goserelin corpusSummary and findings
A case report describes rapid progression to invasive carcinoma following the discontinuation of adjuvant endocrine therapy due to torimifene-induced hepatotoxicity. The patient initially had completely resected intraductal papillary carcinoma. This case highlights the importance of managing treatment-related toxicity and monitoring patients who interrupt therapy.
Abstract
Even 'low-risk' intraductal papillary carcinoma can progress rapidly to invasive disease following unplanned discontinuation of adjuvant endocrine therapy, as illustrated by this case where hepatotoxicity led to treatment cessation and early recurrence. This underscores the critical need for proactive toxicity management, patient education, and consideration of enhanced surveillance for high-risk patients who interrupt therapy.
Background
The study addresses the risk of disease progression in patients with intraductal papillary carcinoma following the discontinuation of adjuvant endocrine therapy. While intraductal papillary carcinoma is often considered low-risk, this case illustrates potential rapid progression to invasive disease when treatment is interrupted. Understanding the implications of treatment cessation is critical for patient management.
Methods
This is a case report detailing a single patient's experience. The patient had a completely resected intraductal papillary carcinoma and was undergoing adjuvant endocrine therapy with torimifene. The therapy was discontinued due to hepatotoxicity, and the patient experienced rapid disease progression.
Results
The primary observation was the rapid progression to invasive carcinoma following the cessation of torimifene due to hepatotoxicity. The case emphasizes the need for careful management of treatment-related toxicity and enhanced surveillance for patients who interrupt therapy.
Interpretation
This case suggests that even low-risk cancers can progress rapidly if adjuvant therapy is discontinued, highlighting the importance of managing side effects and maintaining therapy when possible. The findings align with existing literature on the risks associated with treatment interruption but are limited by the single-patient focus.
Key findings
- Rapid progression to invasive carcinoma after therapy discontinuation.
- Hepatotoxicity led to cessation of torimifene treatment.
- Patient had completely resected intraductal papillary carcinoma.
Limitations
- Single case report
- No quantitative data
- No control group
- Limited generalizability